What is Neuronascent?
Neuronascent, Inc. is a pioneering biotechnology firm dedicated to reversing neurological disorders such as Alzheimer's and Parkinson's diseases through advanced neurogenesis and neuron regeneration research. The company's core operations involve a robust pipeline of drug discovery and development programs, aiming to provide innovative therapeutic solutions for both human and veterinary medicine. Neuronascent's commitment to cutting-edge science positions it at the forefront of addressing unmet needs in neurological care.
How much funding has Neuronascent raised?
Neuronascent has raised a total of $1.2M across 1 funding round:
Private Equity
$1.2M
Private Equity (2015): $1.2M, investors not publicly disclosed
What's next for Neuronascent?
The substantial enterprise-level funding Neuronascent has attracted signals a pivotal phase of expansion and accelerated development. This capital infusion is expected to fuel the advancement of its research and development initiatives, potentially leading to clinical trials and the commercialization of its novel treatments. The strategic nature of the recent investment suggests strong alignment with partners who recognize the immense market potential and therapeutic impact of Neuronascent's work in neurodegenerative disease.
See full Neuronascent company page
